Easton Pharmaceuticals, Inc. (OTCMKTS:EAPH) LOI to acquire anti ageing and beauty products

Today on September 27, 2013, a specialty pharmaceutical company that offers a range of topically applicable therapeutic healthcare products, Easton Pharmaceuticals (OTCMKTS:EAPH) announced signing of the LOI (letter of intent) towards acquisition of Anti-Ageing and beauty care products range. The company will have to perform the due diligence including review of the products range and intellectual property that may form a part of the acquisition, within 60 days period. The products range also include certain products to compliment Easton Pharmaceuticals (OTCMKTS:EAPH)’s medical marijuana initiatives. The intellectual property may include the portfolio of approved as well as applied / pending patents.

The name of company and its product line would remain confidential until closure of final definitive agreement.  Given the closure of the acquisition, Easton Pharmaceuticals (OTCMKTS:EAPH) will get a sound platform to enter the $426 Billion a year Cosmetics Industry. Easton Pharmaceuticals (OTCMKTS:EAPH) is, however, positive about the acquisition and mentions that it has a high probability of closing. As per the agreement both companies have to come to terms within 60 days period to close the final agreement. Regardless of acquisition, it is much anticipated that Easton Pharmaceuticals (OTCMKTS:EAPH) would lend the use of its technology for this product line to improve the efficacy and penetrability.

The product complimenting the company’s medical marijuana initiatives include HEMP based Anti-Ageing Moisturizer which uses natural botanical ingredients including organic herbs besides encompassing HEMP oil – rich in proteins and amino acids and derived from a different form of Cannabis plant. Other line of products includes a skin discoloration treatment gel, an anti-cellulite varicose veins treatment system and an anti-ageing serum rich in Vitamin C.

In other recent development, the company has received the shipment of its main ingredient for final trail samples of Viorra – its lead candidate intended to treat Female Sexual Arousal Disorder. However the company is awaiting the shipment of other ingredients. The trial samples of Viorra and its other products are intended to be shipped to Mexico and parts of Latin America for obtaining governmental regulatory approval.

Leave a Reply

Your email address will not be published. Required fields are marked *